Affinia Therapeutics strengthens its Board of Directors along with raising $60m Series A financing co-led by F-Prime Capital and NEA
– USA, MA – Affinia Therapeutics, an innovative gene therapy company with a platform for rationally designed adeno-associated virus vectors and gene therapies and a mission to develop transformative medicines for devastating diseases, today announced it has closed an oversubscribed $60 million Series A financing co-led by seed venture investors F-Prime Capital and New Enterprise Associates alongside new investor Atlas Venture, with participation from seed investors Alexandria Venture Investments, Lonza and Partners Innovation Fund.…